Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
18 pending office actions • 16 art units • 17 examiners • 0 of 18 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
University of Ulsan Foundation for Industry Cooperation has 18 pending office actions in Medical Devices & Mechanical Engineering. The matters involve 17 distinct examiners across 16 distinct art units, indicating broad distribution across both examiner assignments and technical groupings.
WILLSE, DAVID H is the busiest examiner, with 2 pending matters. That modest concentration offers a limited opportunity for examiner-specific coordination, but most matters remain assigned to separate examination relationships.
The close relationship between the number of matters, examiners, and art units supports a portfolio-management approach organized by technical subject and prosecution stage. Counsel should look for recurring claim concepts and disclosure positions, while preparing responses that account for the distinct art-unit settings.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 10 (56%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 5 (28%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLSE, DAVID H | 2 | 67.3% | +14.0% |
| ABRAHAM, ESAW T | 1 | 94.3% | +3.3% |
| HUPCZEY, JR, RONALD JAMES | 1 | 64.8% | +22.3% |
| RAYMOND, LINNAE ELIZABETH | 1 | 50.4% | +50.4% |
| GEBREMICHAEL, BRUK A | 1 | 22.0% | +23.3% |
| JAHAN, ISRAT | 1 | — | — |
| PAK, YONG D | 1 | 74.7% | +14.2% |
| BOWERS, NATHAN ANDREW | 1 | 59.5% | +31.7% |
| TRAN, JENNY NGAN | 1 | 41.7% | +50.0% |
| JOHNSON, NICOLE F | 1 | 87.4% | +7.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564790 | CATHETER APPARATUS FOR PHOTODYNAMIC THERAPY | JOHNSON, NICOLE F | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352493 | ARTIFICIAL BLOOD VESSEL COMPLEX | WILLSE, DAVID H | 14d |
| 19090293 | METHOD AND DEVICE FOR DECODING ERROR CORRECTING CODE | ABRAHAM, ESAW T | — |
| 18856351 | ARTIFICIAL STRUCTURE FOR PREVENTING OR TREATING LYMPHEDEMA AND CONSTRUCTION METHOD THEREFOR | RAYMOND, LINNAE ELIZABETH | — |
| 18757751 | APPARATUS AND METHOD FOR PROVIDING STEREOSCOPIC VISION TRAINING | GEBREMICHAEL, BRUK A | — |
| 18287891 | SULFIDE-BASED SOLID ELECTROLYTE, PREPARATION METHOD THEREOF, AND ALL-SOLID STATE BATTERY PREPARED THEREFROM | SLIFKA, SARAH A | — |
| 18285669 | NOVEL SUPRAMOLECULAR SELF-ASSEMBLY, CARBON NITRIDE AND PHOTOCATALYST USING SAME, AND MANUFACTURING METHOD THEREFOR | LALISSE, REMY FREDERIC | — |
| 18254546 | PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING FIBROTIC DISEASES, COMPRISING PROGRANULIN PROTEIN OR ACTIVE FRAGMENTS THEREOF AS ACTIVE INGREDIENT | FISCHER, JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352493 | ARTIFICIAL BLOOD VESSEL COMPLEX | WILLSE, DAVID H | 14d |
| 19088877 | RF ABLATION CATHETER FOR TREATING HYPERTROPHIC CARDIOMYOPATHY AND METHOD OF TREATING HYPERTROPHIC CARDIOMYOPATHY BY USING SAME | HUPCZEY, JR, RONALD JAMES | — |
| 18856351 | ARTIFICIAL STRUCTURE FOR PREVENTING OR TREATING LYMPHEDEMA AND CONSTRUCTION METHOD THEREFOR | RAYMOND, LINNAE ELIZABETH | — |
| 18757751 | APPARATUS AND METHOD FOR PROVIDING STEREOSCOPIC VISION TRAINING | GEBREMICHAEL, BRUK A | — |
| 18715840 | CORNEAL ENDOTHELIAL TISSUE TRANSPLANTATION SYSTEM | WILLSE, DAVID H | — |
| 18707174 | SORD AS BIOMARKER FOR PREDICTING PROGNOSIS AFTER LIVER CANCER SURGERY | PAK, YONG D | — |
| 18686154 | CELL CULTURE DEVICE | BOWERS, NATHAN ANDREW | — |
| 18681973 | TYMPANUM IMAGE PROCESSING APPARATUS AND METHOD FOR GENERATING NORMAL TYMPANUM IMAGE BY USING MACHINE LEARNING MODEL TO OTITIS MEDIA TYMPANUM IMAGE | TRAN, JENNY NGAN | — |
| Art Unit | Apps |
|---|---|
| 3781 | 2 |
| 3774 | 2 |
| 2112 | 1 |
| 3794 | 1 |
| 3715 | 1 |
| 3792 | 1 |
| 1645 | 1 |
| 1799 | 1 |
| 2615 | 1 |
| 3796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19090293 | METHOD AND DEVICE FOR DECODING ERROR CORRECTING CODE | ABRAHAM, ESAW T | 2112 | §101§103 | Non-Final OA | — | Pending | Mar 25, 2025 |
| 19088877 | RF ABLATION CATHETER FOR TREATING HYPERTROPHIC CARDIOMYOPATHY AND METHOD OF TREATING HYPERTROPHIC CARDIOMYOPATHY BY USING SAME | HUPCZEY, JR, RONALD JAMES | 3794 | §112DP | Non-Final OA | — | Pending | Mar 24, 2025 |
| 18856351 | ARTIFICIAL STRUCTURE FOR PREVENTING OR TREATING LYMPHEDEMA AND CONSTRUCTION METHOD THEREFOR | RAYMOND, LINNAE ELIZABETH | 3781 | §103§112 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18757751 | APPARATUS AND METHOD FOR PROVIDING STEREOSCOPIC VISION TRAINING | GEBREMICHAEL, BRUK A | 3715 | §103 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18556360 | LOW-LEVEL LASER THERAPY DEVICE USING LED ENDOSCOPE CAP | JAHAN, ISRAT | 3792 | §103 | Final Rejection | — | Pending | Jun 10, 2024 |
| 18715840 | CORNEAL ENDOTHELIAL TISSUE TRANSPLANTATION SYSTEM | WILLSE, DAVID H | 3774 | §103 | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18707174 | SORD AS BIOMARKER FOR PREDICTING PROGNOSIS AFTER LIVER CANCER SURGERY | PAK, YONG D | 1645 | §112 | Non-Final OA | — | Pending | May 03, 2024 |
| 18686154 | CELL CULTURE DEVICE | BOWERS, NATHAN ANDREW | 1799 | §103 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18681973 | TYMPANUM IMAGE PROCESSING APPARATUS AND METHOD FOR GENERATING NORMAL TYMPANUM IMAGE BY USING MACHINE LEARNING MODEL TO OTITIS MEDIA TYMPANUM IMAGE | TRAN, JENNY NGAN | 2615 | §103 | Final Rejection | — | Pending | Feb 07, 2024 |
| 18564790 | CATHETER APPARATUS FOR PHOTODYNAMIC THERAPY | JOHNSON, NICOLE F | 3796 | §103 | Final Rejection | — | Pending | Nov 28, 2023 |
| 18287891 | SULFIDE-BASED SOLID ELECTROLYTE, PREPARATION METHOD THEREOF, AND ALL-SOLID STATE BATTERY PREPARED THEREFROM | SLIFKA, SARAH A | 1759 | §102§103§112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18285669 | NOVEL SUPRAMOLECULAR SELF-ASSEMBLY, CARBON NITRIDE AND PHOTOCATALYST USING SAME, AND MANUFACTURING METHOD THEREFOR | LALISSE, REMY FREDERIC | 1742 | §102§103 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18262341 | STEM CELL IN WHICH IMMUNE CELL TOLERANCE MODULATOR IS OVEREXPRESSED, AND USE THEREOF | PAULUS, ERIN VIRGINIA | 1631 | §103 | Final Rejection | 20d | Pending | Jul 20, 2023 |
| 18352493 | ARTIFICIAL BLOOD VESSEL COMPLEX | WILLSE, DAVID H | 3774 | §102§103 | Final Rejection | 14d | Pending | Jul 14, 2023 |
| 18254546 | PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING FIBROTIC DISEASES, COMPRISING PROGRANULIN PROTEIN OR ACTIVE FRAGMENTS THEREOF AS ACTIVE INGREDIENT | FISCHER, JOSEPH | 1658 | §102§103§112 | Non-Final OA | — | Pending | May 25, 2023 |
| 18058956 | NANOSTRUCTURE-BASED SUBSTRATE FOR SURFACE-ENHANCED RAMAN SPECTROSCOPY, AND MANUFACTURING METHOD THEREFOR | LEE, DA WEI | 2817 | §103 | Final Rejection | 4d overdue | Pending | Nov 28, 2022 |
| 18056766 | RECTUM EXPANDING BALLOON CATHETER | NGO, MEAGAN N | 3781 | §103 | Non-Final OA | 14d | Pending | Nov 18, 2022 |
| 17995024 | STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | 56d | Pending | Sep 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of Ulsan Foundation for Industry Cooperation has 18 pending office actions as of October 2026, spread across 16 art units and 17 examiners.
David H Willse has the most, with 2 of University of Ulsan Foundation for Industry Cooperation's pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
